Načítá se...
Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
Immunocheckpoint inhibitors (ICIs) have become a standard pharmacological therapy in non‐small cell lung cancer (NSCLC). Because brain metastases (BMs) have historically been listed as exclusion criteria in previous clinical trials involving ICIs in advanced NSCLC, the survival benefit from ICI in N...
Uloženo v:
| Vydáno v: | Cancer Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897968/ https://ncbi.nlm.nih.gov/pubmed/33340271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3675 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|